The estimated Net Worth of Roeland Nusse is at least 4.26 百万$ dollars as of 7 March 2024. Roeland Nusse owns over 10,400 units of Bio-Techne Corp stock worth over 3,167,199$ and over the last 14 years he sold TECH stock worth over 800,592$. In addition, he makes 288,759$ as Independent Director at Bio-Techne Corp.
Sign up
Roeland Nusse TECH stock SEC Form 4 insiders trading
Roeland has made over 5 trades of the Bio-Techne Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 10,400 units of TECH stock worth 800,592$ on 7 March 2024.
The largest trade he's ever made was exercising 32,000 units of Bio-Techne Corp stock on 30 August 2023 worth over 716,800$. On average, Roeland trades about 3,064 units every 71 days since 2010. As of 7 March 2024 he still owns at least 43,097 units of Bio-Techne Corp stock.
You can see the complete history of Roeland Nusse stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Roeland Nusse biography
Dr. Roeland Nusse Ph.D. is Independent Director of Bio-Techne Corporation. Dr. Nusse has been a professor or associate professor in the Department of Developmental Biology at Stanford University and an investigator at the Howard Hughes Medical Institute since 1990. He has also been the chair of the Department of Developmental Biology at Stanford since 2007. Dr. Nusse was previously at the Netherlands Cancer Institute (Amsterdam, The Netherlands) as a staff scientist and ultimately head of the Department of Molecular Biology. Dr. Nusse was elected to the United States National Academy of Sciences in April 2010, the European Molecular Biology Organization in 1988, the Royal Dutch Academy of Sciences in 1997, and the American Academy of Arts and Sciences in 2001. Dr. Nusse was awarded the Breakthrough Prize in Life Sciences in 2016. Dr. Nusse earned a bachelor’s degree in biology from the University of Amsterdam and a doctorate in molecular biology from the Netherlands Cancer Institute in 1980.
What is the salary of Roeland Nusse?
As the Independent Director of Bio-Techne Corp, the total compensation of Roeland Nusse at Bio-Techne Corp is 288,759$. There are 14 executives at Bio-Techne Corp getting paid more, with Charles Kummeth having the highest compensation of 11,483,800$.
How old is Roeland Nusse?
Roeland Nusse is 70, he's been the Independent Director of Bio-Techne Corp since 2010. There are no older and 18 younger executives at Bio-Techne Corp.
What's Roeland Nusse's mailing address?
Roeland's mailing address filed with the SEC is 473 Tennessee Ln, Palo Alto, CA 94306, USA.
Insiders trading at Bio-Techne Corp
Over the last 21 years, insiders at Bio-Techne Corp have traded over 37,160,097$ worth of Bio-Techne Corp stock and bought 4,361 units worth 454,370$ . The most active insiders traders include Charles R. Kummeth、Rupert Vessey、John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of 964,850$. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth 99,919$.
What does Bio-Techne Corp do?
bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.
What does Bio-Techne Corp's logo look like?
Complete history of Roeland Nusse stock trades at Bio-Techne Corp
Bio-Techne Corp executives and stock owners
Bio-Techne Corp executives and other stock owners filed with the SEC include:
-
Charles Kummeth,
President, Chief Executive Officer, Director -
Charles R. Kummeth,
CEO, Pres & Director -
James Hippel,
Chief Financial Officer, Executive Vice President - Finance -
David Eansor,
President - Protein Sciences -
Kim Kelderman,
President - Diagnostics and Genomics -
Brenda Furlow,
Senior Vice President, General Counsel, Corporate Secretary -
James T. Hippel,
Exec. VP of Fin. & CFO -
Norman David Eansor,
Pres of Protein Sciences Segment -
Kim Kelderman,
Pres of Diagnostics & Genomics -
Brenda S. Furlow J.D.,
Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer -
Robert Baumgartner,
Independent Chairman of the Board -
Rupert Vessey,
Independent Director -
John Higgins,
Independent Director -
Randolph Steer,
Independent Director -
Roeland Nusse,
Independent Director -
Alpna Seth,
Independent Director -
Joseph Keegan,
Independent Director -
David Clair,
IR Contact Officer -
Julie Bushman,
Independent Director -
Kevin Smyth,
Sr. VP & Chief Digital Officer -
Luca Cicchetti,
Managing Director -
Brenda Everson,
Sr. VP of HR -
Kevin S. Gould,
Sr. VP of Diagnostics Reagents Division -
Struan Robertson,
VP of HR -
Robert M. Gavin,
VP of Corp. Devel. -
Gerry Andros,
VP of Sales and Marketing -
Karen A Holbrook,
Director -
Roger C Lucas,
-
Charles A Dinarello,
-
J. Fernando Bazan,
Chief Technical Officer -
Robert M. Gavin,
Sen. VP Protein Platforms -
Kevin S Gould,
SVP Clinical Controls -
Kevin J Reagan,
Senior VP Biotech -
Gregory J Melsen,
VP Finance and CFO -
Thomas E Oland,
President -
Howard V Oconnell,
Director -
Marcel Veronneau,
Vice Pres-Hematology Oper. -
James A Weatherbee,
Chief Scientific Officers -
Monica Tsang,
Vice President of Research -
Christopher S Henney,
Director -
G A Herbert,
Director -
Harold J Wiens,
-
William Geist,
PRESIDENT, PROTEIN SCIENCES -
Shane Bohnen,
SVP - General Counsel -
Matthew Mc Manus,
President - DGS -
Judith V Klimovsky,
Director